Valoctocogene roxaparvovec

Therapeutic indications

Valoctocogene roxaparvovec is indicated for:

Severe haemophilia A

Population group: only adults (18 years old or older)

Valoctocogene roxaparvovec is indicated for the treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Valoctocogene roxaparvovec is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Active infections

Infectious disease

Chronic hepatic infections, hepatic fibrosis, hepatic cirrhosis

at least one of
Chronic liver disease
Hepatic fibrosis
Cirrhosis of liver
Hepatic insufficiency

Blood, organ, tissue and cell donation

at least one of
Blood unit collection
Organ retrieval operation
Transplantation

Patients with factor VIII inhibitors

at least one of
Anti-factor VIII
Factor VIII inhibitor disorder

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: ROCTAVIAN Solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈